| Name | Title | Contact Details |
|---|---|---|
Evan Ferree |
Staff Vice President, Head of Business Information Security Office | Profile |
Derek Schutz |
VP of Actuarial Services & Analytics | Profile |
Shawn Marks |
SR. Director Technology - IAM Automation | Profile |
Daniel Tapper |
Business Information Security Officer (BISO) | Profile |
Jeff Martin |
Director Information Security | Profile |
Dadson Manufacturing, Inc. is a Grain Valley, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Golden Valley Memorial Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Golden Valley Memorial Hospital is based in Clinton, MO. You can find more information on Golden Valley Memorial Hospital at www.gvmh.org
A Mission to Improve Healthcare. Mitesco, Inc. (OTCQB: MITI) is a public, development stage company whose mission is to acquire and implement technologies and services to improve the quality of care, reduce cost, and enhance consumer convenience. We are focused on developing a portfolio of companies that provide healthcare technology solutions and the team is adept at deal structures supportive of long term organizational value. The holding company structure facilitates profitable growth and enables acquired business to focus on scale. The MITI portfolio of companies will apply leading-edge solutions that emphasize stakeholder value and are based upon sector trends.
Aya Healthcare creates exceptional experiences – for their clinicians, their corporate employees and the healthcare facilities they serve. For healthcare facilities, Aya delivers a robust suite of software and services to manage the procurement of contingent labor. Aya’s platform provides access to one of the largest sources of contract clinicians in the country which improves efficiency, increases quality and reduces costs for healthcare systems. For travel nurses, Aya delivers the best experience in the industry and allows access to the widest base of travel assignments in the United States.
We are a biopharmaceutical company developing first-in-class therapies for cancer. Imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. Telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a potent and specific inhibitor of telomerase. Based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or MF, myelodysplastic syndromes, or acute myelogenous leukemia.